Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 54.5 -0.35% -0.19
AGIO closed down 0.64 percent on Friday, April 16, 2021, on 1.46 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Apr 28
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical AGIO trend table...

Date Alert Name Type % Chg
Cup with Handle Other -0.09%
Doji - Bearish? Reversal -0.09%
Stochastic Reached Overbought Strength -0.09%
Overbought Stochastic Strength -0.09%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.96%
Inside Day Range Contraction 4.96%
Down 3 Days in a Row Weakness 4.96%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.59%
Cup with Handle Other 4.59%
Outside Day Range Expansion 4.59%
Older End-of-Day Signals for AGIO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 4 hours ago
10 DMA Support about 4 hours ago
Down 2 % about 4 hours ago
Down 1% about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Agios Pharmaceuticals, Inc. Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Cancers Hydrogen Metabolism Organic Chemistry Inborn Errors Of Metabolism Glutamate Agios Pharmaceuticals Glutaminase Pyruvate Kinase Deficiency

Is AGIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 58.93
52 Week Low 32.47
Average Volume 751,330
200-Day Moving Average 44.72
50-Day Moving Average 51.55
20-Day Moving Average 51.87
10-Day Moving Average 53.48
Average True Range 2.43
ADX 15.06
+DI 23.41
-DI 12.75
Chandelier Exit (Long, 3 ATRs ) 48.70
Chandelier Exit (Short, 3 ATRs ) 53.84
Upper Bollinger Band 56.13
Lower Bollinger Band 47.60
Percent B (%b) 0.83
BandWidth 16.44
MACD Line 1.04
MACD Signal Line 0.77
MACD Histogram 0.2667
Fundamentals Value
Market Cap 3.79 Billion
Num Shares 69.3 Million
EPS -6.67
Price-to-Earnings (P/E) Ratio -8.20
Price-to-Sales 15.74
Price-to-Book 6.52
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 57.80
Resistance 3 (R3) 57.88 56.93 57.28
Resistance 2 (R2) 56.93 56.14 56.89 57.10
Resistance 1 (R1) 55.81 55.65 55.34 55.73 56.93
Pivot Point 54.86 54.86 54.62 54.82 54.86
Support 1 (S1) 53.74 54.07 53.27 53.66 52.45
Support 2 (S2) 52.79 53.58 52.75 52.28
Support 3 (S3) 51.67 52.79 52.10
Support 4 (S4) 51.59